TargetMol

GLP-1 receptor agonist 9 citrate

Product Code:
 
TAR-T9579L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9579L-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9579L-5mg5mg£422.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9579L-10mg10mg£589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9579L-1mL1 mL * 10 mM (in DMSO)£610.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9579L-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9579L-50mg50mg£1,179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9579L-100mg100mg£1,564.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
GLP-1 receptor agonist 9 citrate is an agonist of GLP-1.
CAS:
T9579L
Formula:
C38H39ClFN3O12
Molecular Weight:
784.18
Pathway:
GPCR/G Protein
Purity:
0.98
SMILES:
C[C@]1(OC2=C(O1)C=CC=C2C3CCN(CC3)CC4=NC5=C(N4C[C@H]6OCC6)C=C(C=C5)C(O)=O)C7=C(F)C=C(Cl)C=C7.OC(C(O)=O)(CC(O)=O)CC(O)=O
Target:
Glucagon Receptor

References

Gary E. Aspnes, et al. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destin?es ? ?tre utilis?es dans le traitement de la nash/nafld et de maladies associ?es. Patent WO2020234726 A1.